Total Payments
$20,349
2024 Payments
$3,200
Companies
3
Transactions
17
Payment Breakdown by Category
Research$20,281 (99.7%)
Food & Beverage$68.44 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $20,281 | 14 | 99.7% |
| Food and Beverage | $68.44 | 3 | 0.3% |
Payments by Type
Research
$20,281
14 transactions
General
$68.44
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $20,281 | 14 | $0 (2024) |
| GlaxoSmithKline, LLC. | $47.92 | 2 | $0 (2019) |
| BioMarin Pharmaceutical Inc. | $20.52 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,200 | 1 | PFIZER INC. ($3,200) |
| 2023 | $8,461 | 6 | PFIZER INC. ($8,461) |
| 2022 | $7,350 | 5 | PFIZER INC. ($7,350) |
| 2020 | $1,270 | 2 | PFIZER INC. ($1,270) |
| 2019 | $68.44 | 3 | GlaxoSmithKline, LLC. ($47.92) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/08/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/21/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/07/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $2,720.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/07/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $816.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/25/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/11/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SJIA WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/26/2023 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $2,150.00 | Research |
| Study: EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SJIA WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/20/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $1,975.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/15/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SJIA WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/08/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $925.00 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/30/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $2,427.60 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 08/30/2022 | PFIZER INC. | XELJANZ (Drug) | — | Cash or cash equivalent | $1,096.91 | Research |
| Study: A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 09/25/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 04/24/2020 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TOFACITINIB CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/20/2019 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: IMMUNOLOGY | ||||||
| 10/18/2019 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $31.25 | General |
| Category: IMMUNOLOGY | ||||||
| 03/29/2019 | BioMarin Pharmaceutical Inc. | — | Food and Beverage | In-kind items and services | $20.52 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A LONGTERM OPENLABEL FOLLOWUP STUDY OF TOFACITINIB FOR TREATMENT OF JUVENILE IDIOPATHIC ARTHRITIS JIA | PFIZER INC. | $11,811 | 8 |
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| EFFICACY SAFETY TOLERABILITY AND PHARMACOKINETICS OF TOFACITINIB FOR TREATMENT OF SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS SJIA WITH ACTIVE SYSTEMIC FEATURES IN CHILDREN AND ADOLESCENT SUBJECTS | PFIZER INC. | $4,000 | 3 |
About Dr. Beth Gottlieb, MD
Dr. Beth Gottlieb, MD is a Pediatric Rheumatology healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952470221.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Beth Gottlieb, MD has received a total of $20,349 in payments from pharmaceutical and medical device companies, with $3,200 received in 2024. These payments were reported across 17 transactions from 3 companies. The most common payment nature is "" ($20,281).
Ad
Practice Information
- Specialty Pediatric Rheumatology
- Location New Hyde Park, NY
- Active Since 11/08/2006
- Last Updated 07/08/2007
- Taxonomy Code 2080P0216X
- Entity Type Individual
- NPI Number 1952470221
Products in Payments
- XELJANZ (Drug) $20,281
- BENLYSTA (Biological) $47.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Rheumatology Doctors in New Hyde Park
Dr. Joyce Hui-Yuen, M.d., M.sc, M.D., M.SC
Pediatric Rheumatology — Payments: $242.47
Pediatric Rheumatology $242.47
Lydia Thomas, Md, MD
Pediatric Rheumatology — Payments: $124.99
Pediatric Rheumatology $124.99
Barbara Eberhard, Md, MD
Pediatric Rheumatology — Payments: $106.76
Pediatric Rheumatology $106.76
Dr. Heather Walters, Md, MD
Pediatric Rheumatology — Payments: $88.88
Pediatric Rheumatology $88.88
Nina Skaria, Np, NP
Pediatric Rheumatology
Pediatric Rheumatology